肺癌并发上腔静脉综合征同步放化疗35例临床观察  

Clinical observation for treatment of lung cancer secondary to superior vena cava syndrome by using concurrent chemoradiotherapy among 35 patients

作　　者：张雪彬[1] 

机构地区：[1]内蒙古通辽市医院肿瘤放疗科,028000

出　　处：《中国实用医药》2013年第36期58-59,共2页China Practical Medicine

摘　　要：目的探讨同步放化疗在治疗肺癌并发上腔静脉综合征中的作用。方法对35例肺癌并发上腔静脉综合征患者采取同步放化疗。结果完全缓解率71.4%,部分缓解率20%,总有效率91.4%。6个月、12个月、18个月生存率分别为:97.1%(34/35)、71.4%(25/35)、34.3%(12/35)。结论对肺癌并发上腔静脉综合征患者同步放化疗大多数患者能够耐受,是提高有效率及生存率的综合治疗方法。Objective To investigate the therapeutic effect of concurrent chemoradiotherapy in the treatment of lung cancer secondary to superior vena cava syndrome. Methods 35 lung cancer patients were treated effectively with concurrent chemoradiotherapy. Results Among 35 patients, complete response 71.4%, partial response 20%, the overall response rate（CR＋PR） was 91.4%. The survival rate of 6 months, 12 months, 18 months was 97.1%（34/35）,71.4%（25/35）, 34.3%（12/35） respectively. Conclusion Concurrent chemoradiotherapy is an effective method in the treatment of lung cancer secondary to superior vena cava syndrome with well acceptable, so it is a comprehensive method to improve efficiency and survival rate.

关 键 词：肺癌 上腔静脉综合征 同步放化疗 毒副作用 SUPERIOR vena cava syndrome(SVCS) 

分 类 号：R734.2[医药卫生—肿瘤]